Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Insider filings

<< Previous

Bullboard Posts

Next >>

Comment by MikeStockon Mar 04, 2021 9:22am

133 Views

Post# 32713511

RE:RE:RE:RE:Insider filings

Unless they have different rules in their contract, it's not a gurantee that they sell when they vest (and I assume those numbers of pre-split). If they believe the price will rise significantly, they will hold. The hard part is how the tax on works as they will either have to pay the tax or sell a portion of the vested shares to cover the tax. So we could see a bunch sold (particularly for the non-execs) as they might not have the cash on hand to cover the tax.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta